A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 901–1,000 of 3,965
McMillan, D. H., van der Velden, J. L. J., Lahue, K. G., Qian, X., Schneider, R. W., Iberg, M. S., Nolin, J. D., Abdalla, S. T., Casey, D. T., Tew, K. D., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85717 · Cited by 44
Aiello, M., Bertorelli, G., Bocchino, M., Chetta, A. A., Fiore-Donati, A., Fois, A. G., Marinari, S., Oggionni, T., Polla, B., Rosi, E., et al. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.02.005 · Cited by 46
Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
Kuttruff, C. A., Ferrara, M., Bretschneider, T., Hoerer, S., Handschuh, S., Nosse, B., Romig, H., Nicklin, P. L., & Roth, G. J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00312 · Cited by 50
Update in Pulmonary Fibrosis 2018
Sgalla, G., Kulkarni, T., Antin-Ozerkis, D. E., Thannickal, V. J., & Richeldi, L. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0542up · Cited by 43
van der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A. M., Stutvoet, S., Fagard, L., de Wal, K. V., & Helmer, E. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1424 · Cited by 43
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Duitman, J., van den Ende, T., & Spek, C. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101547 · Cited by 48
The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
Marwitz, S., Turkowski, K., Nitschkowski, D., Weigert, A., Brandenburg, J., Reiling, N., Thomas, M., Reck, M., Drömann, D., Seeger, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01550 · Cited by 44
“A retrospective study in idiopathic pulmonary fibrosis (IPF), which is discussed to be driven by aberrant TGFβ (12), found that patients treated with Pirfenidone had a significantly reduced risk of developing lung cancer during their follow-up phase (13).”
BackgroundInfluentialKronborg-White, S. B., Andersen, C. U., Kohberg, C., Hilberg, O., & Bendstrup, E. M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01452-7 · Cited by 43
Liu, Y., Zhong, W., Zhang, J., Chen, W., Lu, Y., Qiao, Y., Zeng, Z., Huang, H., Zou, F., 孟小晶, et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739220 · Cited by 46
“Previous studies using lung biopsies from IPF patients reported a diminution of autophagy (Patel et al., 2012; Araya et al., 2013) and some from animal model illustrated that TGF-β1 could mediate dysfunction of the autophagy response during lung fibrosis (Sosulski et al., 2015).”
BackgroundInfluentialThe Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
Cunha, P. S., Laranjo, S. M., Heijman, J., & Oliveira, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879984 · Cited by 44
“In the clinical setting, Pirfenidone (a drug that is inhibitory of TGFβ signaling) is approved as an oral anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (274), and its use”
BackgroundPCSK6 and Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Allen, R. J., Lorenzo-Salazar, J. M., Molyneaux, P. L., Ma, S., Joseph, C., Kim, J. S., Guillén‐Guío, B., Hernández-Beeftink, T., Kropski, J. A., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202205-0845oc · Cited by 53
Self-citationGuo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205948 · Cited by 41
“, 2018), as has been demonstrated in numerous randomized, placebo-controlled phase III trials (King et al., 2014; Noble et al., 2016).”
BackgroundA novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M. R. J., Ryerson, C. J., Cottin, V., Beasley, M. B., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0048pp · Cited by 49
Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis
Calver, J., Parmar, N. R., Harris, G., Lithgo, R. M., Stylianou, P., Zetterberg, F. R., Gooptu, B., MacKinnon, A. C., Carr, S. B., Borthwick, L. A., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107300 · Cited by 50
The need for patient-centred clinical research in idiopathic pulmonary fibrosis
Russell, A., Sprangers, M. A. G., Wibberley, S., Snell, N. J. C., Rose, D. M., & Swigris, J. J. (2015) · BMC Medicine · doi:10.1186/s12916-015-0475-4 · Cited by 44
Self-citationExercise training in idiopathic pulmonary fibrosis: is it of benefit?
Vainshelboim, B. (2016) · Breathe · doi:10.1183/20734735.006916 · Cited by 52
Larsen, B. T., Smith, M. L., Elicker, B. M., Fernández, J., Arbo, G., Pereira, C. A. C., & Leslie, K. O. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0299-sa · Cited by 42
Self-citationLiang, Z., Hoffman, L. A., Nouraie, M. S., Kass, D. J., Donahoe, M. P., Gibson, K. F., Saul, M. I., & Lindell, K. O. (2016) · Journal of Palliative Medicine · doi:10.1089/jpm.2016.0258 · Cited by 47
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Mooney, J. J., Raimundo, K., Chang, E. Y., & Broder, M. S. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0426-2 · Cited by 48
Wu, J., Li, X., Zhao, M., Huang, H., Sun, W., & Gao, Y. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700103 · Cited by 43
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease
Danese, S., Bonovas, S., Lopez, A., Fiorino, G., Sandborn, W. J., Rubin, D. T., Kamm, M. A., Colombel, J., Sands, B. E., Vermeire, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.032 · Cited by 42
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 45
Graney, B. A., & Lee, J. S. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s144425 · Cited by 44
Lee, S. H., Yeo, Y., Kim, T., Lee, H. L., Lee, J. H., Park, Y. B., Park, J. S., Kim, Y. H., Song, J. W., Jhun, B. W., et al. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0091 · Cited by 50
Chen, G., Ni, Y., Nagata, N., Xu, L., Zhuge, F., Nagashimada, M., Kaneko, S., & Ota, T. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0255-4 · Cited by 42
Indications for lung transplant referral and listing
Shweish, O., & Dronavalli, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.09 · Cited by 49
Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis
Marcoux, V. S., Wang, M., Burgoyne, S., Fell, C. D., Ryerson, C. J., Sajobi, T. T., & Johannson, K. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201904-335rl · Cited by 41
Increased flux through the mevalonate pathway mediates fibrotic repair without injury
Larson‐Casey, J. L., Vaid, M., Gu, L., He, C., Cai, G.-Q., Ding, Q., Davis, D., Berryhill, T. F., Wilson, L. S., Barnes, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127959 · Cited by 46
Rozenberg, D., Sitzer, N., Porter, S., Weiss, A. J., Colman, R., Reid, W. D., Shapera, S., Fisher, J. H., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.12.364 · Cited by 43
Shaish, H. A., Ahmed, F. S., Lederer, D. J., D’Souza, B. M., Armenta, P. M., Salvatore, M. M., Saqi, A., Huang, S., Jambawalikar, S., & Mutasa, S. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-068oc · Cited by 40
Self-citationEllison, G. M., Colley, L. S., O’Brien, K. A., Roberts, K. A., Agbaedeng, T. A., & Ross, M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602183 · Cited by 43
“Clinical trials with anti-fibrotic agents have shown promise in reversing progression of pulmonary fibrosis, as evidenced with nintedanib (247) and pirfenidone (248), which were approved by the FDA more than 6 years ago (249).”
BackgroundThe Diagnosis and Treatment of Pulmonary Fibrosis
Kreuter, M., Müller-Ladner, U., Costabel, U., Jonigk, D. D., & Heußel, C. P. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0018 · Cited by 57
Popmihajlov, Z., Sutherland, D., Horan, G. S. B., Ghosh, A., Lynch, D. A., Noble, P. W., Richeldi, L., Reiss, T. F., & Greenberg, S. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001060 · Cited by 50
Self-citationInhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts
Dubey, S., Dubey, P. K., Umeshappa, C. S., Ghebre, Y. T., & Krishnamurthy, P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30684 · Cited by 45
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient
Meyer, K. C., Danoff, S. K., LANCASTER, L. H., & Nathan, S. D. (2015) · CHEST Journal · doi:10.1378/chest.14-2475 · Cited by 46
Self-citationHepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease
Hackett, T., & Osei, E. T. (2021) · Cells · doi:10.3390/cells10082145 · Cited by 52
Seeliger, B., Carleo, A., Wendel‐Garcia, P. D., Fuge, J., Montes‐Worboys, A., Schuchardt, S., Molina‐Molina, M., & Prasse, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837680 · Cited by 44
“Pirfenidone and nintedanib attenuate the mean decline in forced vital capacity significantly to a similar extent (King et al., 2014; Richeldi et al., 2014; Raghu et al., 2015).”
BackgroundPulmonary hypertension in interstitial lung disease: an area of unmet clinical need
Dhont, S., Zwaenepoel, B. A. C., Vandecasteele, E. H., Brusselle, G., & Pauw, M. D. (2022) · ERJ Open Research · doi:10.1183/23120541.00272-2022 · Cited by 48
Kataoka, K., Nishiyama, O., Ogura, T., Mori, Y., Kozu, R., Arizono, S., Tsuda, T., Tomioka, H., Tomii, K., Sakamoto, K., et al. (2023) · Thorax · doi:10.1136/thorax-2022-219792 · Cited by 41
Mochizuka, Y., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., et al. (2023) · Respirology · doi:10.1111/resp.14523 · Cited by 41
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martínez, F. J., Oldham, J. M., Valenzuela, C., Gordat, M., Liu, Y., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001563 · Cited by 46
Peikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
“168 In the Phase 2 PIROUETTE (Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction) trial of patients with HFpEF and CMR evidence of myocardial fibrosis (defined as ECV ≥ 27%), pirfenidone significantly reduced myocardial fibrosis and NT-proBNP levels compared…”
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Azuma, A., Inomata, M., & Nishioka, Y. (2015) · Core evidence · doi:10.2147/ce.s82905 · Cited by 57
Lung transplantation in IIP : A review
Brown, A. W., Kaya, H., & Nathan, S. D. (2015) · Respirology · doi:10.1111/resp.12691 · Cited by 44
Self-citationDouble-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
Huang, H. F., Dai, H. P., Kang, J., Chen, B. Y., Sun, T. Y., & Xu, Z. (2015) · Medicine · doi:10.1097/md.0000000000001600 · Cited by 41
Outcome Measures for Clinical Trials in Interstitial Lung Diseases
Lammi, M. R., Baughman, R. P., Birring, S. S., Russell, A., Ryu, J. H., Scholand, M. B., Distler, O., LeSage, D., Sarver, C., Antoniou, K. M., et al. (2015) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x11666150619183527 · Cited by 44
Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study
Furuya, K., Sakamoto, S., Shimizu, H., Sekiya, M., Kinoshita, A., Isshiki, T., Sugino, K., Matsumoto, K., & Homma, S. A. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.03.026 · Cited by 40
Pompe, E., de Jong, P. A., Lynch, D. A., Leßmann, N., Išgum, I., van Ginneken, B., Lammers, J. J., & Hoesein, F. A. A. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01814-2016 · Cited by 40
Airway Complications After Lung Transplantation
Frye, L., & Machuzak, M. S. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.07.010 · Cited by 43
Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis
O’Brien, K., Introne, W. J., Akal, O., Akal, T., Barbu, A., McGowan, M. P., Merideth, M. A., Seward, S. L., Gahl, W. A., & Gochuico, B. R. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.07.012 · Cited by 40
Clukers, J., Lanclus, M., Mignot, B., Holsbeke, C. S. V., Roseman, J., Porter, S., Gorina, E., Kouchakji, E., Lipson, K. E., Backer, W. D., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0918-5 · Cited by 45
Self-citationDistler, O., Volkmann, E. R., Hoffmann‐Vold, A., & Maher, T. M. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1668269 · Cited by 44
Yoshikawa, T., Otsuka, M., Chiba, H., Ikeda, K., Mori, Y., Umeda, Y., Nishikiori, H., Kuronuma, K., & Takahashi, H. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1060-y · Cited by 40
Guler, S. A., Clarenbach, C., Brutsche, M. H., Hostettler, K., Brill, A.-K., Schertel, A., Geiser, T. K., & Funke-Chambour, M. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-266oc · Cited by 39
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41
Real-life prevalence of progressive fibrosing interstitial lung diseases
Gagliardi, M., Berg, D. V., Heylen, C. E., Koenig, S., Hoton, D., Tamirou, F., Pieters, T., Ghaye, B., & Froidure, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03481-8 · Cited by 43
Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs
Nishikiori, H., Kuronuma, K., Hirota, K., Yama, N., Suzuki, T., Onodera, M., Onodera, K., Ikeda, K., Mori, Y., Asai, Y., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02269-2021 · Cited by 42
Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., & Glaspole, I. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2018.1507 · Cited by 40
Self-citationEvaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
Ntatsoulis, K., Karampitsakos, Τ., Tsitoura, E., Stylianaki, E.-A., Matralis, A. N., Tzouvelekis, A., Antoniou, K. M., & Aidinis, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687397 · Cited by 45
Aging Immune System and Its Correlation With Liability to Severe Lung Complications
Li, Y., Wang, C., & Peng, M. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.735151 · Cited by 45
Fainberg, H. P., Oldham, J. M., Molyneaux, P. L., Allen, R. J., Kraven, L. M., Fahy, W. A., Porte, J., Braybrooke, R., Saini, G., Karsdal, M. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00173-x · Cited by 46
“4,6,8,12,13 Conventional linear regression was acceptable for imputing data in the first year, similar to previous studies, including 12-month daily home spirometry studies.”
Stenzel, W., Mammen, A. L., Gallay, L., Holzer, M., Kleefeld, F., Benvéniste, O., Allenbach, Y., Allenbach, Y., Benvéniste, O., Damoiseaux, J. G. M. C., et al. (2024) · Neuromuscular Disorders · doi:10.1016/j.nmd.2024.104453 · Cited by 45
Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation
Justet, A., Thabut, G., Manali, E. D., Molina‐Molina, M., Kannengiesser, C., Cadranel, J. L., Cottin, V., Gondouin, A., Nunès, H., Magois, E., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01875-2017 · Cited by 40
Keenan, C. R., Langenbach, S. Y., Jativa, F., Harris, T., Li, M., Chen, Q., Xia, Y., Gao, X., Schuliga, M. J., Jaffar, J., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00738 · Cited by 43
Tsai, M., Chang, W., Liao, S., Chang, K., Sheu, C., & Kuo, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081958 · Cited by 42
Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
Jo, H. E., Corte, T. J., Glaspole, I., Grainge, C., Hopkins, P. M.-A., Moodley, Y. P., Reynolds, P. N., Chapman, S. A., Walters, E. H., Zappala, C. J., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0846-2 · Cited by 45
Self-citationInhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
Overed-Sayer, C. L., Miranda, E., Dunmore, R., Marin, E. L., Beloki, L., Rassl, D. M., Parfrey, H., Carruthers, A. M., Chahboub, A., Koch, S., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214000 · Cited by 40
S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
Behr, J., Günther, A., Bonella, F., Dinkel, J., Fink, L., Geiser, T., Geissler, K. H., Gläser, S., Handzhiev, S., Jonigk, D. D., et al. (2021) · Respiration · doi:10.1159/000512315 · Cited by 42
Hou, J., Ji, Q., Ji, J., Ju, S., Xu, C., Yong, X., Xu, X., Muddassir, M., Chen, X., Xie, J., et al. (2021) · Theranostics · doi:10.7150/thno.54217 · Cited by 45
Protective function of interleukin‐22 in pulmonary fibrosis
Gu, P., Wang, D., Zhang, J., Wang, X., Chen, Z., Gu, L., Liu, M., Meng, F., Yang, J., Cai, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.509 · Cited by 40
Swaminathan, A. C., Hellkamp, A. S., Neely, M. L., Bender, S. D., Paoletti, L., White, E. S., Palmer, S. M., Whelan, T. P. M., & Dilling, D. F. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-589oc · Cited by 44
Raman, L., Stewart, I. D., Barratt, S. L., Chua, F., Chaudhuri, N., Crawshaw, A., Gibbons, M., Hogben, C., Hoyles, R. K., Kouranos, V., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00423-2022 · Cited by 43
Bhardwaj, S., Gautam, R. K., & Kushwaha, S. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.08.003 · Cited by 55
Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis
Todd, N. W., Atamas, S. P., Luzina, I. G., & Galvin, J. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1067609 · Cited by 40
Matsushima, S., & Ishiyama, J. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00252.2016 · Cited by 38
Khadawardi, H. A., & Mura, M. (2016) · Respirology · doi:10.1111/resp.12945 · Cited by 40
Severe idiopathic pulmonary fibrosis: what can be done?
Caminati, A., Cassandro, R., Torre, O., & Harari, S. A. (2017) · European Respiratory Review · doi:10.1183/16000617.0047-2017 · Cited by 39
Ohkubo, H., Nakagawa, H., & Niimi, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.10.003 · Cited by 44
Decoding fibrosis: Mechanisms and translational aspects
Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.009 · Cited by 40
Drug and chemical induced photosensitivity from a clinical perspective
Ibbotson, S. H. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00011e · Cited by 41
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 39
Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis
Okamoto, M., Izuhara, K., Ohta, S., Ono, J., & Hoshino, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-6657-4_9 · Cited by 36
Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis
Bilgili, H., Białas, A. J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081232 · Cited by 40
Yang, L., Liu, G., Fu, L., Zhong, W., Li, X., & Pan, Q. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111283 · Cited by 38
Bava, E. P., George, J., Tarique, M., Iyer, S., Sahay, P., Gomez, B. A., Edwards, D., Giri, B., Sethi, V., Jain, T., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141108 · Cited by 40
Wang, G., Zhou, X., Guo, Z., Huang, N. J., Li, J., Lv, Y.-F., Han, L., Zheng, W., Xu, D., Chai, D., et al. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2035629 · Cited by 45
Belhassen, M., Dalon, F., Nolin, M., & Van Ganse, E. (2021) · Respiratory Research · doi:10.1186/s12931-021-01714-y · Cited by 38
Gerckens, M., Schorpp, K., Pelizza, F., Wögrath, M., Reichau, K., Ma, H., Dworsky, A.-M., Sengupta, A., Stoleriu, M. G., Heinzelmann, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3673 · Cited by 37
Epidemiology and real-life experience in progressive pulmonary fibrosis
Valenzuela, C., & Cottin, V. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000908 · Cited by 37
Hou, J., Huang, Y. L., Fu, L., Sun, M., Wang, L., Guo, R., Chen, L., & Lv, C. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03640 · Cited by 38
Warsinske, H., Wheaton, A. K., Kim, K. K., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00183 · Cited by 38
The clinical impact of major comorbidities on idiopathic pulmonary fibrosis
Suzuki, A., & Kondoh, Y. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2016.11.004 · Cited by 46
P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis
Müller, T., Fay, S., Vieira, R. P., Karmouty‐Quintana, H., Cicko, S., Ayata, C. K., Zissel, G., Goldmann, T., Lungarella, G., Ferrari, D., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01028 · Cited by 42
Salisbury, M. L., Tolle, L. B., Xia, M., Murray, S., Tayob, N., Nambiar, A. M., Schmidt, S. L., Lagstein, A., Myers, J. L., Gross, B. H., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.08.025 · Cited by 37
Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease
Khor, Y. H., Goh, N. S. L., Glaspole, I., Holland, A. E., & McDonald, C. F. (2018) · Respiratory Care · doi:10.4187/respcare.06334 · Cited by 43
Self-citationTherapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension
Poble, P.-B., Phan, C., Quatremare, T., Bordenave, J., Thuillet, R., Cumont, A., Huertas, A., Tu, L., Dorfmüller, P., Humbert, M. J. C., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801659r · Cited by 41
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.